חובות לטווח קצר של החברה: Absci Corporation (ABSI)

Absci combines artificial intelligence capabilities with biology to design antibodies, integrating its developments into the laboratories of the largest pharmaceutical behemoths. The asset's market value, clearly illustrated on this chart, is accompanied by the current metric 0.00. Long-term generative AI contracts provide the company with stability while results for its own molecules are awaited. The business relies on the digitalization of medicine and the optimization of healthcare data management.

This indicator measures the total volume of financial liabilities for Absci (ABSI) with a maturity of up to one year. Monitoring short-term liabilities allows for an assessment of liquidity and the risk of cash flow gaps. For an AI antibody developer, such a metric reflects the balance between debt capital and R&D expenditures. A reduction in the debt load confirms financial stability. A stable level of debt guarantees protection against default while maintaining the pace of technological leadership.